| Similar Articles |
|---|
 |
The Motley Fool
October 15, 2007
Brian Lawler |
A Surprising Decision for Telik It still doesn't look like the pharma's lead drug is helping anyone get better. Investors, take note.   |
The Motley Fool
June 6, 2007
Brian Lawler |
Is Telik Insane? Shares of Telik fall after the FDA puts a halt to trials with its lead drug. Even at this reduced share price, investors should stay far away from this pharma. |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
BusinessWeek
December 29, 2003
Gene G. Marcial |
Faster Pulse At Esperion Esperion Therapeutics shares may zip up, says Mark Monane of investment firm Needham. Pfizer, Genentech, or Aventis could strike a deal for any of Esperion's four cardiovascular drugs now in trials, he says. |
The Motley Fool
December 27, 2006
Brian Lawler |
Telik Falls Short Shares of another biopharma fall after disappointing clinical trial results. |
BusinessWeek
December 11, 2006
Gene G. Marcial |
Two Allos Drugs Are Taking Aim At Cancer Allos Therapeutics is the next biotech to watch. |
The Motley Fool
February 27, 2007
Brian Lawler |
Three Strikes for Telik Investors, there's not much in the pipeline at this small biotech company. |
The Motley Fool
September 26, 2007
Brian Lawler |
Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures. |
BusinessWeek
October 17, 2005
Gene G. Marcial |
Encysive Is Breathing Easy Among biotechs favored by Mark Monane of investment firm Needham is Encysive Pharmaceuticals. |
The Motley Fool
January 3, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Telik... Gorman-Rupp... China Netcom... Penson Worldwide... |
The Motley Fool
December 22, 2003
Jeff Hwang |
Pfizer Stuffs Its Pipeline Pfizer extends its reach in cardiovascular disease with Esperion Therapeutics. |
BusinessWeek
February 13, 2006
Gene G. Marcial |
Apoplexy: Renovis Takes Aim Renovis, a young biopharma developing treatments for pain, trauma, and stroke, could be joining the big leagues. |
